Crossmark Global Holdings Inc. Takes $1.21 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

Crossmark Global Holdings Inc. acquired a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 8,120 shares of the biotechnology company's stock, valued at approximately $1,212,000.

A number of other institutional investors also recently made changes to their positions in the business. Assetmark Inc. bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $331,000. Jackson Square Capital LLC purchased a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth about $1,441,000. Harbor Capital Advisors Inc. raised its stake in Ascendis Pharma A/S by 67.2% in the third quarter. Harbor Capital Advisors Inc. now owns 87,302 shares of the biotechnology company's stock worth $13,035,000 after buying an additional 35,102 shares in the last quarter. Pursue Wealth Partners LLC purchased a new stake in Ascendis Pharma A/S in the third quarter worth about $217,000. Finally, Rice Hall James & Associates LLC boosted its position in Ascendis Pharma A/S by 5.9% during the 3rd quarter. Rice Hall James & Associates LLC now owns 160,614 shares of the biotechnology company's stock valued at $23,981,000 after acquiring an additional 8,958 shares in the last quarter.

Ascendis Pharma A/S Trading Down 1.4 %

NASDAQ ASND traded down $1.75 on Thursday, hitting $124.28. 974,853 shares of the company traded hands, compared to its average volume of 445,610. The business's 50 day moving average price is $132.04 and its 200-day moving average price is $132.86. The company has a market capitalization of $7.54 billion, a price-to-earnings ratio of -13.54 and a beta of 0.66. Ascendis Pharma A/S has a 52-week low of $90.13 and a 52-week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. As a group, sell-side analysts predict that Ascendis Pharma A/S will post -7.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ASND shares. StockNews.com lowered Ascendis Pharma A/S from a "hold" rating to a "sell" rating in a research report on Tuesday. Wells Fargo & Company increased their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a research report on Tuesday, September 17th. The Goldman Sachs Group raised their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Citigroup increased their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a "buy" rating in a research note on Tuesday, September 17th. Finally, JPMorgan Chase & Co. lowered their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating on the stock in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $195.92.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.